TABLE 1.
POLE variant groups, patient clinical and demographic characteristics for the CARIS cohort
| POLE ExoD driver TMB-H | ||||
|---|---|---|---|---|
| Clinicopathologic factors | POLE variant TMB-L (Group 1) | POLE ExoD driver (Group 2) | POLE ExoD driver + POLE Variant (Group 3) | POLE Variant TMB-H (Group 4) |
| Colorectal cancer | ||||
| No. of patients | 36/92 | 11/92 | 24/92 | 21/92 |
| mTMB | 6.0 (3–9) | 115 (61–216) | 264.5(114–414) | 33 (10–461) |
| MSS | 36 | 11 | 21 | 11 |
| MSI | 0 | 0 | 3 | 10 |
| <50 yrs | 6 | 5 | 14 | 8 |
| ≥50 yrs | 30 | 6 | 10 | 13 |
| Female | 19 | 1 | 6 | 8 |
| Male | 17 | 10 | 18 | 13 |
| Endometrial cancer | ||||
| No. of patients | 95/307 | 37/307 | 57/307 | 118/307 |
| mTMB | 7 (3–9) | 52 (21–314) | 219 (53–520) | 17.50 (10–273) |
| MSS | 90 | 35 | 41 | 23 |
| MSI | 5 | 2 | 16 | 95 |
| <50 yrs | 6 | 6 | 10 | 5 |
| ≥50 yrs | 89 | 31 | 47 | 113 |
| Ovarian cancer | ||||
| No. of patients | 24/48 | 12/48 | 8/48 | 4/48 |
| mTMB | 5.0 (4–9) | 69 (31–379) | 145 (51–394) | 14.50 (10–21) |
| MSS | 24 | 12 | 6 | 2 |
| MSI | 0 | 0 | 2 | 2 |
| <50 yrs | 4 | 4 | 5 | 3 |
| ≥50 yrs | 20 | 8 | 3 | 1 |
Abbreviations: MMR, mismatch repair; MSI, microsatellite instability; MSS, microsatellite stability; mTMB, median tumor mutational burden; yrs, years.